Is Carisma Therapeutics Stock a Good Investment?
Carisma Therapeutics Investment Advice | CARM |
- Examine Carisma Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Carisma Therapeutics' leadership team and their track record. Good management can help Carisma Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Carisma Therapeutics' business and its evolving consumer preferences.
- Compare Carisma Therapeutics' performance and market position to its competitors. Analyze how Carisma Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Carisma Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Carisma Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Carisma Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Carisma Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Carisma Therapeutics Stock
Researching Carisma Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 27.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.52. Carisma Therapeutics last dividend was issued on the 8th of March 2023. The entity had 1:20 split on the 8th of March 2023.
To determine if Carisma Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Carisma Therapeutics' research are outlined below:
| Carisma Therapeutics generated a negative expected return over the last 90 days | |
| Carisma Therapeutics has high historical volatility and very poor performance | |
| Carisma Therapeutics has some characteristics of a very speculative penny stock | |
| Carisma Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 14.92 M. Net Loss for the year was (86.88 M) with loss before overhead, payroll, taxes, and interest of (43.24 M). | |
| Carisma Therapeutics generates negative cash flow from operations | |
| About 27.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Steven Kelly of 500000 shares of Carisma Therapeutics at 0.5 subject to Rule 16b-3 |
Carisma Therapeutics Quarterly Cash And Short Term Investments |
|
Carisma Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Carisma Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Carisma Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Carisma Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Carisma Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.3 | -0.27 | 0.03 | 10 | ||
2024-11-07 | 2024-09-30 | -0.26 | -0.31 | -0.05 | 19 | ||
2023-08-10 | 2023-06-30 | -0.6 | -0.49 | 0.11 | 18 | ||
2019-03-01 | 2018-12-31 | -1.6 | -1.8 | -0.2 | 12 | ||
2019-11-12 | 2019-09-30 | -2.3 | -2.6 | -0.3 | 13 | ||
2018-08-14 | 2018-06-30 | -2.8 | -3.2 | -0.4 | 14 | ||
2022-08-08 | 2022-06-30 | -2.6 | -3.2 | -0.6 | 23 | ||
2018-05-15 | 2018-03-31 | -2.8 | -2.2 | 0.6 | 21 |
Carisma Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 20.83 M.Market Cap |
|
Carisma Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.87) | (0.92) | |
| Return On Capital Employed | (1.08) | (1.14) | |
| Return On Assets | (0.87) | (0.92) | |
| Return On Equity | (3.77) | (3.58) |
Determining Carisma Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Carisma Therapeutics is a good buy. For example, gross profit margin measures Carisma Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Carisma Therapeutics' profitability and make more informed investment decisions.
Basic technical analysis of Carisma Stock
As of the 31st of January, Carisma Therapeutics shows the Standard Deviation of 6.02, mean deviation of 4.1, and Risk Adjusted Performance of (0.11). Carisma Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Carisma Therapeutics information ratio and skewness to decide if Carisma Therapeutics is priced correctly, providing market reflects its regular price of 0.5 per share. As Carisma Therapeutics is a penny stock we also strongly suggest to validate its jensen alpha numbers.Carisma Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Carisma Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Carisma Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Carisma Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Carisma Therapeutics' Outstanding Corporate Bonds
Carisma Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Carisma Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Carisma bonds can be classified according to their maturity, which is the date when Carisma Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Understand Carisma Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Carisma Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (2.21) | |||
| Mean Deviation | 4.1 | |||
| Coefficient Of Variation | (697.59) | |||
| Standard Deviation | 6.02 | |||
| Variance | 36.2 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (1.52) | |||
| Treynor Ratio | (2.22) | |||
| Maximum Drawdown | 30.07 | |||
| Value At Risk | (11.54) | |||
| Potential Upside | 7.5 | |||
| Skewness | (0.09) | |||
| Kurtosis | 3.17 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (2.21) | |||
| Mean Deviation | 4.1 | |||
| Coefficient Of Variation | (697.59) | |||
| Standard Deviation | 6.02 | |||
| Variance | 36.2 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (1.52) | |||
| Treynor Ratio | (2.22) | |||
| Maximum Drawdown | 30.07 | |||
| Value At Risk | (11.54) | |||
| Potential Upside | 7.5 | |||
| Skewness | (0.09) | |||
| Kurtosis | 3.17 |
Consider Carisma Therapeutics' intraday indicators
Carisma Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Carisma Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 260144.0 | |||
| Daily Balance Of Power | (0.17) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 0.48 | |||
| Day Typical Price | 0.49 | |||
| Price Action Indicator | 0.015 | |||
| Period Momentum Indicator | (0.01) |
Carisma Stock media impact
Far too much social signal, news, headlines, and media speculation about Carisma Therapeutics that are available to investors today. That information is available publicly through Carisma media outlets and privately through word of mouth or via Carisma internal channels. However, regardless of the origin, that massive amount of Carisma data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Carisma Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Carisma Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Carisma Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Carisma Therapeutics alpha.
Carisma Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Carisma Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Carisma Therapeutics Corporate Management
| Terry Shields | Senior Resources | Profile | |
| Kenneth Locke | Senior Operations | Profile | |
| MD FACS | Chief Officer | Profile | |
| MBA JD | General Secretary | Profile | |
| Tom Wilton | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.12) | Return On Assets | Return On Equity |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Carisma Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.